Real-world data supports the use of nirmatrelvir-ritonavir in reducing the risk for severe COVID-19 outcomes among nonhospitalized patients.
A multipronged exercise rehabilitation approach can improve function and quality of life in patients with severe respiratory ...
Interstitial lung disease was a common adverse event with 10 of the 15 FDA-approved antibody-drug conjugates, according to data from FAERS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback